Q-omics provides the consensus-scored GOLGA6D profile across patient tissues and cancer cell-line models. GOLGA6D expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GOLGA6D is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, GOLGA6D RNA expression shows 8,316 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight LUAD, BRCA, and LIHC as cancer lineages where GOLGA6D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6D survival associations across molecular data types. GOLGA6D RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6D RNA expression–survival associations across cancer types. High GOLGA6D expression shows unfavorable associations in LUAD, MESO, ACC, UCS and READ, but favorable associations in SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for GOLGA6D RNA expression.
This table summarizes GOLGA6D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6D shows lower tumor expression in BRCA. The BRCA box plot shows higher GOLGA6D RNA expression in normal versus tumor tissue (log2 FC = −0.002, t-test p = .026).
This table shows molecular features associated with GOLGA6D in patient tissues and cancer cell lines. In patient samples, GOLGA6D shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA6D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and OVARY.
